FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma
Open Access
- 14 May 2022
- journal article
- retracted article
- Published by Wiley in Applied Bionics and Biomechanics
- Vol. 2022, 1-11
Abstract
Background. Skin cutaneous melanoma is one of most aggressive type of cancers worldwide. Therefore, the identification of SKCM biomarkers is of great importance. FLG gene is one of the genes that encode proteins involved in epidermal formation. This was the first time to study the role of FLG in the prognosis and immune infiltrates of skin cutaneous melanoma. Methods. We downloaded the somatic mutation data of 471 SKCM patients from the Cancer Genome Atlas (TCGA) database and analyzed the mutation profiles with MafTools package. The expression of FLG and the overall survival in SKCM were analyzed by GEPIA. Additionally, univariate and multivariate Cox analyses were used to compare several clinical features with survival rates. We used TIMER to investigate FLG expression and collection of immune infiltration levels in SKCM, as well as cumulative survival in SKCM. Meanwhile, we also used CIBERSORT to investigate the association between FLG and cancer immune infiltration. In addition, gene set enrichment analysis (GSEA) was performed using the TCGA dataset. Furthermore, data from GEO and HPA was used to validate the results. Results. Single nucleotide polymorphism (SNP) happened more frequently than insertion or deletion, and CT was the most common of SNV in SKCM. We selected the first 15 mutated genes by analyzing 471 melanoma samples, and the prognosis analysis showed that only the high expression of mutated FLG gene was significantly correlated with the poor prognosis of SKCM. Multivariate Cox analysis showed that age, the worse tumor status, less lymph node metastasis, and FLG expression were independent factors for prognosis. Specifically, lower infiltration levels of B cell, CD8+ T cells, neutrophils, and dendritic cells correlated with poor survival outcomes in SKCM. GSEA revealed that FLG is closely related to cancer pathways and epidermal cell proliferation. In addition, the previous conclusions can be verified from external data from GEO and HPA. Conclusion. The discovery of mutant gene FLG as a biomarker of SKCM helps elucidate how changes in the immune environment promote the occurrence of cutaneous melanoma. Further analysis suggested that FLG might be a new predictor of SKCM prognosis.Keywords
Funding Information
- China Postdoctoral Science Foundation (501100002858, 2018BSHEDZZ91)
- Postdoctoral Science Foundation of Shaanxi Province (501100002858, 2018BSHEDZZ91)
This publication has 32 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The Human Protein Atlas as a proteomic resource for biomarker discoveryJournal of Internal Medicine, 2011
- The role of genetics and environment in the rise of childhood food allergyClinical & Experimental Allergy, 2011
- Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severityAllergy, 2011
- Towards a knowledge-based Human Protein AtlasNature Biotechnology, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survivalProceedings of the National Academy of Sciences, 2009
- Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigenJournal of Allergy and Clinical Immunology, 2009
- Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitisNature Genetics, 2006